SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bob s who wrote (272)6/10/1997 11:12:00 PM
From: carl w. trygstad   of 1972
 
The annual meeting was very upbeat. Perhaps more so than last year. They know the results of the Merck trial but can not disclose them. Merck is actively persuing the HIV DNA vaccine. Vical is excited with the cancer data which actually looks promising.
To dragonfly: Baxter did not pursue the hemophilia vaccine because factor 8 is a very complex molecule and the titers were not very high. Less complex proteins like erythopoeitin work well.
They do not predict immediate profits but expect to be profitable in 2-3 years. I am long in this one.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News